Being an inflamed peritoneal dialysis patient - A Dante's journey

Contributions to Nephrology

Volumn 150, Issue , 2006, Pages 144-151

  Carrero, Juan Jesús ^a   Axelsson, Jonas ^a   Avesani, Carla Maria ^a   Heimbürger, Olof ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CHRONIC DISEASE; HUMAN; INFLAMMATION; KIDNEY DISEASE; PERITONEAL DIALYSIS; REVIEW;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; INFLAMMATION; KIDNEY DISEASES; PERITONEAL DIALYSIS;

EID: 33745231689     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000093514     Document Type: Review

References (26)

1. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005;20:1048-1056.
2. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307-1320.
3. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
4. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 2004;109:II2-II10.
5. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002;62:1791-1798.
6. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, Sturtevant JM, Isbel NM, Nicol DL, Johnson DW: Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2001;12:814-821.
7. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin J-M: C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002;62:1417-1422.
8. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M: IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005;67:1216-1233.
9. Stenvinkel P, Heimbürger O, Jogestrand T: Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002;39:274-282.
10. Wang AY, Sea MM, Tang N, Sanderson JE, Lui SF, Li PK, Woo J: Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 2004;15: 3134-3143.
11. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson JE: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004;15: 2186-2194.
12. Sjoland JA, Pedersen RS, Jespersen J, Gram J: Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. Nephron Clin Pract 2005;100:c105-c110.
13. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, Ritz E, Bierhaus A, Nawroth PP, Zeier M: Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006;17:199-207.
14. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
15. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimbürger O, Lindholm B: Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004;24:327-339.
16. Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, Giacone G, Cottini E, Tripepi G, Malatino LS, Zoccali C: Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001;16:1459-1464.
17. Chung SH, Heimbürger O, Stenvinkel P, Wang T, Lindholm B: Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 2003;23:174-183.
18. Balakrishnan VS, Guo D, Rao M, Jaberm BL, Tighiouart H, Freeman RL, Huang C, King AJ, Pereira BJ, Group HS: Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 2004;65:1449-1460.
19. Losito A, Kalidas K, Santoni S, Jeffery S: Association of interleukin-6-174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003;64:616-622.
20. Gillerot G, Goffin E, Michel C, Evenepoel P, Biesen WV, Tintillier M, Stenvinkel P, Heimbürger O, Lindholm B, Nordfors L, Robert A, Devuyst O: Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005;67:2477-2487.
21. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimbürger O, Barany P, Hoff CM, Holmes CJ, Suliman M, Lindholm B, Schalling M, Nordfors L: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003:S172-S176.
22. Yao Q, Nordfors L, Axelsson J, Heimbürger O, Qureshi AR, Barany P, Lindholm B, Lönnqvist F, Schalling M, Stenvinkel P: Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. Atherosclerosis 2005;182:105-111.
23. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N: Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001;21(suppl 3):S102-S107.
24. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimbürger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC: Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003;14:2338-2344.
25. Furuya R, Odamaki M, Kumagai H, Hishida A: Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2005; in press.
26. Krishnan M, Tam P, Wu G, Breborowicz A, Oreopoulos DG: Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes? Int Urol Nephrol 2005;37:409-418.